Watermark
  Back to Search Results

BGB-3111-106

Completed

A Two-Part Phase 1 Study to Investigate the Safety and Tolerability of Supratherapeutic Dose of Zanubrutinib and Effect of Zanubrutinib on Cardiac Repolarization in Healthy Subjects

BeOne Study ID Info icon SVG graphic used for tooltips or additional information.

BGB-3111-106

ClinicalTrials.gov ID Info icon SVG graphic used for tooltips or additional information.

NCT03432884

Study Overview

Sex: All Info icon SVG graphic used for tooltips or additional information.

Age: 18 Years / 55 Years

No Study Documents

Study Overview

Sex: All Info icon SVG graphic used for tooltips or additional information.

Age: 18 Years / 55 Years

No Study Documents